2 years to 21 years
Male or Female
There remains a significant unmet medical need for more effective treatment options for pediatric subjects with solid tumors. Overall solid tumors make up to 30% of all cancers in children. Approximately 80% of these tumors are cured with conventional approaches. This is a multicenter, open-label, Phase 1/2 study of lenvatinib in combination with everolimus in pediatric subjects with relapsed or refractory solid tumors. This study will be performed on pediatric subjects with solid tumors, which were resistant to conventional therapy, and for whom there are no alternative therapies that might lead to cure.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.